Introduction: Post-prandial hyperglycemia (PPH) among people with diabetes is a well-known clinical challenge to diabetes management.
INTRODUCTION
It is well established that better glycemic control among people with diabetes, as indicated by HbA1c values, is associated with a reduced risk of microvascular complications related to diabetes, and there is evidence that glycemic control reduces the risk of macrovascular complications in type 1 diabetes mellitus (T1DM) and in type 2 diabetes mellitus (T2DM) when control is achieved early in the course of the disease [1] [2] [3] [4] .
While research and diabetes management practices have long focused on HbA1c and fasting plasma glucose as indicators of glycemic control, more recent research highlights the importance of considering post-prandial blood glucose (PPG) as well for a more complete understanding of glycemic control [5] . There is now growing evidence that post-prandial hyperglycemia (PPH) may be particularly important for improving diabetes control, thereby reducing the risk of diabetes-related complications [2, 6] . Further, PPG control is particularly challenging for people with diabetes who take bolus insulin and must calculate and time their dose, which requires coordination with their daily scheduling, as well as remembering to take doses with them [7] .
Recent research suggests that PPH has a negative impact on a number of health and daily functioning outcomes in people with diabetes [2] . There is evidence that PPH (or elevated post-challenge glucose following an oral glucose tolerance test) is associated with an increased incidence of cardiovascular disease (CVD) and cardiovascular events [8] [9] [10] [11] [12] . PPH is also associated with reduced cognitive functioning among aged people with T2DM [13] . Further, research suggests that PPH (or elevated post-challenge glucose) increases the risk of pancreatic cancer mortality, CVD mortality, and all-cause mortality [9, [14] [15] [16] [17] [18] .
Given the negative health and functioning impacts associated with PPH among people with diabetes, there is also likely to be an economic burden related to PPH. While the economic cost of diabetes care and treatment is a well-known burden to healthcare budgets [19] , little is known about the specific costs associated with PPH. The purpose of this study is to investigate the burden of PPH among people with T1DM and T2DM and related short-term costs associated with PPH in the areas of diabetes management, use of healthcare resources, and work.
METHODS
A web survey of people diagnosed with T1DM or T2DM and treated with self-administered basal plus bolus insulin was conducted in Germany, the UK, and the USA. Prior to commencement, the study received ethics approval from Copernicus Group IRB (# TBG1- .
Survey Development
The process of survey development, including conducting focus groups and cognitive debriefing of the survey, followed Food and Drug Administration (FDA) guidelines for development of patient-reported outcomes (PROs) and accepted methodology for concept elicitation to ensure face validity and that items are comprehensive, relevant, and understandable to respondents [20] . As the survey collected data on the patient perspective, as per FDA guidelines, patients were considered the gold standard in generating item content. Nine semi-structured focus groups with a total of 77 people diagnosed with T1DM or T2DM and taking bolus insulin were conducted in Germany (n = 20), the UK (n = 17), and the USA (n = 40) to inform survey development. Transcript data from the focus groups were analyzed using adapted grounded theory [21] , and thematic saturation occurred by the eighth focus group. Following survey development, survey items were assessed using cognitive debriefing with 12 individuals diagnosed with diabetes to ensure that survey instructions and items were clear, relevant, easy to understand, and inoffensive. Additionally, the cognitive debriefing was used to ensure that survey structure and recall periods were appropriate. Respondents were given the survey in the local language, and a professional translator was used to ensure consistency. The final survey was composed of 85 questions and took respondents approximately 30 min to complete. Respondents were given modest honoraria (approximately $15 USD per respondent) for completing the survey.
Participants
The web survey was administered to panels of respondents in Germany, the UK, and the USA between July and November of 2013.
Inclusion/exclusion criteria required that participants be adults aged 18 years and older who were diagnosed with T1DM or T2DM by a physician or healthcare professional, and treated with bolus insulin therapy but not using pre-mixed insulin or glucagon-like peptide-1 analogs, with or without oral anti-diabetic drug (OAD) use, were eligible to complete the survey. Approximately, 7% of people approached for the survey were eligible to complete the survey based on the inclusion and exclusion criteria. Recruitment quotas were also used for country, age, work status, diabetes type, and method of insulin administration to achieve adequate sampling across various groups and to ensure a representative sample.
Survey Variables
All survey items were self-reported by respondents, and survey items included [19] . Due to non-significant results, costs of additional physician visits associated with PPH were not estimated for Germany.
Data Analysis
All data were analyzed using SPSS Statistics Software, version 22 (IBM Corporation, Armonk, NY, USA). Analyses included descriptive statistics (means, standard deviations, ranges, and frequency percentages) and measures of association (comparison of means and cross-tabulations). Significance tests were also conducted. For comparison of means between two groups, t tests were used, and for comparison of means among three or more groups, analysis of variance was used [29] . The Chi-square test statistic was used to determine the significance of associations between categorical variables. All analyses were conducted by country and by diabetes type.
Among people with T2DM, analyses revealed that results were generally similar whether or not respondents were taking OADs, so these results are not presented here. Comparisons were not possible for people with T1DM, as the vast majority were not taking OADs. were significantly more likely than those with T2DM to indicate being in ''good,'' ''very good,'' or ''excellent'' health (69.1% vs. 49.6%, P\0.001). Respondents with T1DM were significantly more likely than those with T2DM to indicate that their diabetes was ''well'' or ''very well'' controlled (66.3% vs.
RESULTS

Sample Descriptive Statistics
49.6%, P\0.001). The full sample descriptive statistics by country are presented in Table 1 .
Respondent Experiences of PPH
PPH was a frequent occurrence among respondents; 61.9% of respondents reported experiencing PPH in the past week, and 30.0% experienced three or more episodes of PPH in the past week ( Table 2 ). On average, The average number of days since respondents' last incident of out-of-range post-prandial BG (either hyperglycemia or hypoglycemia) was 7.5 days, suggesting that many who have such events experience them frequently.
Respondents in the USA were significantly more likely to report experiencing PPH in the past week (66.6%) compared to those in Germany (63.0%) and the UK (53.4%, P\0.01). Additionally, respondents in the USA reported a significantly greater average number of incidents of PPH in the past week (2.0), compared to respondents in the UK (1.5) and Germany (1.5, P\0.01). Experience of PPH did not differ significantly by diabetes type.
PPH and Missed Work Time and Work
Productivity Issues
Among working respondents whose most recent episode of out-of-range PPG was PPH (as opposed to post-prandial hypoglycemia or being unsure), 27.0% reported any missed work time due to that episode of PPH (Table 3) .
More specifically, 13.7% of respondents indicated that they went in late to work due to PPH, 18.6% indicated that they left early, and 9.9% reported missing a full day of work. On average, respondents reported a total of 168.2 min of missed work time in the past week due to BG being out-of-range after eating (either PPH or post-prandial hypoglycemia). There were no significant differences in reported missed work time by diabetes type or by country. A majority of working respondents (70.7%) also reported that they experienced any kind of work productivity issues due to this last episode Chi-square/analysis of variance tests indicate significant differences by country: * P\0.05; ** P\0.01; *** P\0.001 SD standard deviation, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus a The question about physical activity at work was only asked of employed respondents Chi-square/t tests indicate significant differences by diabetes type: *** P\0.001 PPH post-prandial hyperglycemia, SD standard deviation, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus a Data were trimmed by 5% at top level to exclude probable reporting errors (n = 859) b Data were trimmed by 5% at top level to exclude probable reporting errors (n = 867) more likely to report that they found it difficult to focus due to PPH (62.8%) compared to those with T1DM (43.5%, P\0.01). Respondents with T2DM were also significantly more likely to indicate that they were less productive at work due to PPH (50.0%) compared to those with T1DM (37.4%, P\0.05). Respondents in Germany were significantly more likely to report any work productivity issues due to PPH (83.5%) compared to those in the USA (64.5%) and UK (61.6%, P\0.01). Compared to respondents in the USA and UK, respondents in Germany were also significantly more likely to report that they made more mistakes at work (Germany, 37.1%; USA, 24.7%; UK, 19.2%, P\0.05) and found it difficult to focus (Germany, 64.9%; USA, 46.2%; UK, 50.7%, P\0.05) due to PPH.
The impact of PPH on missed work time and reduced work functioning/productivity is shown in Table 3 .
PPH and BG Measurement
Respondents reported measuring BG 3.2 times on an average day and an average of 1.6 extra times compared to a normal day on days they experience symptoms of hyperglycemia. There were significant differences in frequency of BG measurement by whether or not respondent experienced PPH in the past week ( Fig. 1) .
Respondents who experienced PPH in the past week reported measuring their BG a significantly greater number of times on an average day compared to respondents who did not experience PPH in the past week (3.7 vs.
2.5, P\0.001). This is a difference of 1.2 tests This suggests that those who experienced PPH measure their BG more frequently than those without PPH in the previous week both in general, on an average day, and when they experience symptoms of hyperglycemia.
Results were similar by diabetes type and by country.
PPH and Healthcare Resource Utilization
Respondents who experienced PPH were significantly more likely to use healthcare resources than those without PPH. Annual costs of additional physician office visits related to PPH were £210.00 GBP in the UK (2.0 additional visits; £105 GBP per visit [28] ; equivalent cost in USD was $322.77) and $132.30 in the USA (0.9 additional visits; $147 per visit [19] ). As the association between PPH and physician office visits for diabetes care was not significant among German respondents, office visit costs due to PPH were not estimated for Germany. Cost estimates by diabetes type and country are shown in Table 5 .
DISCUSSION
Consistent with prior research [2] , this study has shown that PPH is a frequent occurrence among people with T1DM and T2DM. While there is much discussion in the literature about Nevertheless, the survey used a recall period of 1 week for experience of PPH, which focus groups used to develop the survey indicated was appropriate. Selection bias may also have affected results. As with all studies relying on data from Internet surveys, respondents were drawn from panels of people who were required to be literate and have access to computers and the Internet. In the three countries studied, however, rates of literacy and internet use are both high. For instance, in the UK, the literacy rate is 99% [31] , and approximately 83% of households had access to the internet in 2013 [32] . Additionally, given the cross-sectional, observational nature of the study, the results must be interpreted with caution. Causation may not be assumed in the associations found in the analyses. For instance, the association between PPH and healthcare contact among respondents does not necessarily mean that PPH causes more frequent doctor visits and calls/ emails. There could be other unobserved factors associated with PPH that increase healthcare contact or additional BG measurement.
Moreover, physician confirmation of respondent diabetes diagnosis and other clinical values was not possible due to the panel format of the internet survey. Thus, it is possible that some survey participants reported a diagnosis of diabetes when they had no such diagnosis in reality or reported their diabetes type inaccurately. It is unlikely, however, that such respondents were great enough in number to have an impact on the overall results. Potential respondents were not informed prior to the screener that only people with diabetes would be eligible to complete the survey. Clinical values, including BG measurements, were also not obtained. Such values would capture a more accurate measure of PPH, including the level of hyperglycemia, and may explain some differences in results by diabetes type. Last, further research is needed to explore other potential costs related to PPH and to estimate costs that are more difficult to measure. Future research could also explore how cross-country differences in factors such as diabetes care and treatment may affect the economic burden of PPH.
CONCLUSIONS
This is the first study to address an economic burden associated specifically with PPH among people with diabetes. The findings show that there are substantial costs associated with PPH, which should be included when calculating the cost of diabetes. These costs are the result of lost work productivity, increased diabetes management, and healthcare resource utilization. Reducing the incidence of PPH among people with diabetes would benefit not only patients but also payers, the healthcare system, and employers. 
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